Royalty Pharma plc Class A Ordinary Shares vs Under Armour Inc Class A — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B), while Under Armour Inc Class A trades at $4.81 (market cap $2.07B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 12.2× Under Armour Inc Class A's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Under Armour Inc Class A for 18 Days on average.
| RPRX | UA | |
|---|---|---|
Market Cap | $25.27B | $2.07B |
Volume | 3,671,183 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.96 | $7.88 |
52-Week Low | $35.44 | $3.96 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $32.50B | $3.05B |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UA) trades at $4.75, up 1.06% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability metrics, including a -9.99% net income margin. Cash flow remains negative at -$362M for 2025, while analyst consensus shows 40% buy ratings amid ongoing operational challenges.
Outlook remains cautious with revenue guidance cuts and competitive pressures. Investment opportunity exists if turnaround strategies succeed, but risks include sustained negative cash flow, weak consumer demand, and high debt levels. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →